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Abstract Post-stroke dysphagia is common, associated
with poor outcome and often requires non-oral feeding/
fluids. The relationship between route of feeding and
outcome, as well as treatment with glyceryl trinitrate
(GTN), was studied prospectively. The Efficacy of
Ni t r ic Oxide in Stroke (ENOS) t r ia l assessed
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transdermal GTN (5 mg versus none for 7 days) in
4011 patients with acute stroke and high blood pressure.
Feeding route (oral = normal or soft diet; non-oral =
nasogastric tube, percutaneous endoscopic gastrostomy
tube, parenteral fluids, no fluids) was assessed at base-
line and day 7. The primary outcome was the modified
Rankin Scale (mRS) measured at day 90. At baseline,
1331 (33.2%) patients had non-oral feeding, were older,
had more severe stroke and more were female, than
2680 (66.8%) patients with oral feeding. By day 7,
756 patients had improved from non-oral to oral feed-
ing, and 119 had deteriorated. Non-oral feeding at base-
line was associated with more impairment at day 7
(Scandinavian Stroke Scale 29.0 versus 43.7;
2p < 0.001), and worse mRS (4.0 versus 2.7;
2p < 0.001) and death (23.6 versus 6.8%; 2p = 0.014)
at day 90. Although GTN did not modify route of feed-
ing overall, randomisation ≤6 h of stroke was associated
with a move to more oral feeding at day 7 (odds ra-
tio = 0.61, 95% confidence intervals 0.38, 0.98;
2p = 0.040). As a proxy for dysphagia, non-oral feeding
is present in 33% of patients with acute stroke and
associated with more impairment, dependency and
death. GTN moved feeding route towards oral intake
if given very early after stroke.
Clinical Trial Registration
Clinical Trial Registration-URL: http://www.controlled-
trials.com. Unique identifier: ISRCTN99414122.
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Introduction
Dysphagia (difficulty in swallowing) is a common com-
plication after stroke affecting up to 65% of patients,
many of whom are asymptomatic [1] or have symptoms
that are not thought to be related to swallowing prob-
lems. Although many patients recover swallowing spon-
taneously, 11–50% still have dysphagia at 6 months [2,
3]; conversely, a significant proportion of patients are
able to swallow safely within 1–2 weeks [1, 3]. Post-
stroke dysphagia (PSD) is associated with a poor out-
come for multiple reasons: first, it is a manifestation of
severe stroke and therefore is associated with increased
death , dependency, disabi l i ty, impairment and
institutionalisation; [4] second, it causes aspiration of
foods, liquids and oral secretions and therefore
pneumonia [5–7], which in itself leads to death; [6]
and third, poor recognition and management leads to
dehydration and malnutrition. In the acute phase, the
presence of dysphagia leads to changes in the feeding
of patients from oral routes to the use of enteral feeding
tubes or parenteral fluids.
Although multiple advances have been made in the
very early management of stroke (e.g. with thromboly-
s i s , a s p i r i n , me ch a n i c a l t h r omb e c t omy a nd
hem i c r an i e c t omy ) and s e conda r y p r ev en t i o n
(antithrombotics, blood pressure lowering, lipid lower-
ing, carotid endarterectomy), PSD remains a neglected
research area and its optimal management, including
treatment, have yet to be defined. Nevertheless, stroke
guidelines recommend assessment of swallowing within
24 h and patients with an unsafe swallow are recom-
mended to be nil by mouth; these recommendations
constitute a key performance indicator in many stroke
services. A number of trials have investigated the treat-
ment of dysphagia, including acupuncture, behavioural
therapy, physical stimulation, neuromuscular electrical
stimulation and pharyngeal electrical stimulation
[8–11], and several have given encouraging results
[12]. In respect of drug treatment, a small pilot
randomised trial suggested that nifedipine (a calcium
channel blocker that relaxes oesophageal smooth mus-
cle) might improve swallowing, and metoclopramide (a
dopamine D2-receptor antagonist with antiemetic and
gastric prokinetic activity) might reduce the incidence
of pneumonia [13, 14]. Conversely, lisinopril (an angio-
tensin converting enzyme inhibitor) failed to prevent
pneumonia [15].
Here we describe the natural history and outcomes of
patients with feeding problems in the acute phase of
stroke using data from the large ‘Efficacy of Nitric
Oxide in Stroke’ (ENOS) trial [16–19]. We also report
the effect of transdermal glyceryl trinitrate (GTN, a ni-
tric oxide (NO) donor that relaxes smooth muscle)
hypothesising that it might improve the oesophageal
phase of swallowing and therefore return patients to oral
feeding and a normal diet [17]. Of relevance, loss of
a1ß1 soluble guanylate cyclase, the major NO receptor,
leads to moyamoya and achalasia [20], the latter dem-
onstrating the potential relationship between NO and
swallowing. Since GTN might improve functional out-
come if administered very early (<6 h), as seen in the
ENOS and RIGHT trials [19, 21, 22], we have also
assessed its effect on feeding route in this subgroup of
patients.
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Methods
ENOS Trial
The protocol, statistical analysis plan, baseline characteristics
and main results for ENOS (ISRCTN99414122) have been
published previously [16–19]. Brief information on the trial
design is given in the Supplement.
Route of Feeding and Definitions
ENOS did not record specific information on dysphagia
or aspiration but collected data on route of feeding at
baseline and day 7 [17]. As such, feeding route is a
clinical consequence of dysphagia and its clinical recog-
nition. Feeding route was defined using a pragmatic six-
level ordered categorical scale comprising normal diet,
soft diet, nasogastric tube, percutaneous endoscopic
gastrostomy tube, intravenous or subcutaneous fluids
and no feeding/fluids [17]. At day 7, death was added
as a seventh level. This scale has not been used before
or validated in the context of clinometric aspects such
as face, content and construct validity. The explanation
for no feeding or fluids was not collected but may re-
flect treatment for cerebral oedema or palliation.
Binary analyses were performed on oral feeding (nor-
mal and soft diet) versus non-oral feeding/fluids (nil by
mouth = enteral tube, parenteral fluids, no feeding/fluids
and death if at day 7), and this binary information was
used as a minimisation variable at the time of
randomisation [17, 19]. Definitions for other outcomes
are given in the statist ical analysis plan [17].
Information on pneumonia and chest infection was ob-
tained from serious adverse event (SAE) reports as de-
termined by local investigators and no formal definitions
of these events were set; SAEs were adjudicated by
experts blinded to treatment allocation. Respiratory tract
infection (RTI) was considered as a composite of pneu-
monia, chest infection and/or exacerbation of chronic
obstructive pulmonary disease (COPD).
Statistics
All analyses were exploratory, by intention to treat, and
no correction for multiplicity of testing was made. Data
are shown as number (%) or mean (standard deviation).
Comparisons between groups used binary logistic re-
gression, Cox proportional hazards regression (death),
ordinal logistic regression (OLR, for ordered categorical
variables, e.g. feeding route) or multiple linear regres-
sion (continuous or pseudo continuous data such as
modified Rankin Scale [mRS], Barthel Index [BI],
health utility status). Results are given as odds ratio
(OR) or mean difference (MD), with 95% confidence
intervals (95% CI); p < 0.05 is considered significant.
The assumption of proportionality of odds for OLR was
tested using the likelihood ratio. Analyses were per-
formed using SAS version 9.3.
Results
Feeding Route
Since feeding route was a minimisation variable used at the
time of randomisation, baseline information was available for
all 4011 patients enrolled into ENOS. 43.3% of patients were
on a normal diet at baseline, with 23.5% on a soft diet, 5.6%
receiving fluids and/or food via a nasogastric tube, 0.2% food
and/or fluids by a gastrostomy feeding tube, 18.1% receiving
parenteral fluids and 9.3% no fluids or food by any route
(Table 1). When aggregating feeding route into patients re-
ceiving oral (normal or soft diet) versus non-oral nutrition/
fluids (tube feeding, parenteral fluids or none), one third of
patients were not taking fluids or food bymouth; just 43.3% of
patients were on a normal diet at baseline with 56.7% of pa-
tients exhibiting some form of swallowing abnormality; and
altogether, 66.8% of patients were taking some form of oral
feeding, and 33.2% no oral feeding (Supplementary Fig. I).
Patients on non-oral feeding were significantly older
(+5.4 years), more likely to be female (+6.9%) and have a
history of hypertension (+3.9%) and have more severe stroke
(SSS −13.7 points, TACS +36.3%) and high systolic blood
pressure and heart rate (+2.4 mmHg, +1.8 beats per minute)
on inclusion to the study (Table 1). Similar findings were seen
in patients randomised within 6 h of onset (Supplementary
Table I).
Data on feeding route at day 7 were missing for 14 (0.35%)
patients. By day 7, 756 of 1328 (56.9%) patients had im-
proved from non-oral to oral feeding whereas 119 of 2669
(4.5%) had deteriorated moving from oral to non-oral feeding,
or had died (Supplementary Table II). Overall, there was a
significant move to improved feeding route over the first
7 days of monitoring, adjusted common odds ratio 2.67,
95% CI 2.44–2.93, 2p < 0.001 (Fig. 1). Data on feeding route
beyond day 7 were not collected.
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Table 1 Baseline characteristics of patients on oral versus-non oral-feeding/fluids at baseline
All Non-oral Oral Difference (95% CI) 2p
Number of participants 4011 1331 2680
Age (years) 70.3 (12.2) 73.9 (11.6) 68.5 (12.1) 5.4 (4.6, 6.2) <0.001
Sex, male (%) 2297 (57.3) 701 (52.7) 1596 (59.6) −6.9 (−10.1, −3.6) <0.001
Medical history (%)
Previous stroke 594 (14.8) 192 (14.4) 402 (15.0) −0.6 (−2.9, 1.7) 0.63
Hypertension 2607 (65.0) 900 (67.6) 1707 (63.7) 3.9 (0.8, 7.0) 0.014
Ischaemic heart disease 669 (16.7) 228 (17.1) 441 (16.5) 0.8 (−1.8, 3.3) 0.55
Scandinavian Stroke Scale 33.7 (13.2) 24.6 (12.4) 38.3 (11.0) −13.7 (−14.5, −12.9) <0.001
Blood pressure (mmHg)
Systolic 167.2 (19.0) 168.8 (19.4) 166.5 (18.7) 2.4 (1.1, 3.7) <0.001
Diastolic 89.5 (13.1) 89.0 (13.3) 89.8 (13.0) −0.8 (−1.7, 0.1) 0.069
Heart rate (bpm) 77.5 (14.7) 78.7 (15.8) 76.9 (14.1) 1.8 (0.8, 2.8) <0.001
Stroke type (%)
Ischaemic 3342 (83.3) 1086 (81.6) 2256 (84.2) −2.6 (−5.1, −0.1) 0.039
Haemorrhagic 629 (15.7) 234 (17.6) 395 (14.7) 2.8 (0.4, 5.3) 0.020
Time to randomisation (hours) 26.0 (12.9) 25.4 (12.9) 26.3 (12.8) −0.8 (−1.7, 0.0) 0.052
Syndrome (%) [23]
Total anterior 1209 (30.1) 724 (54.4) 485 (18.1) 36.3 (33.3, 39.3) <0.001
Partial anterior 1251 (31.2) 378 (28.4) 873 (32.6) −4.2 (−7.2, −1.2) 0.007
Posterior 154 (3.8) 25 (1.9) 129 (4.8) −2.9 (−4.0, −1.8) <0.001
Lacunar 1397 (34.8) 204 (15.3) 1193 (44.5) −29.2 (−31.9, −26.5) <0.001
Symptoms (%)
Dysphasia 1610 (40.1) 813 (61.1) 797 (29.7) 31.3 (28.2, 34.5) <0.001
Neglect 1068 (29.9) 601 (55.1) 467 (18.8) 36.3 (33.0, 39.6) <0.001
Side of lesion (%)
Right 2091 (52.1) 645 (48.5) 1446 (54.0) −5.5 (−8.8, −2.2) 0.001
Left 1903 (47.4) 678 (50.9) 1225 (45.7) 5.2 (1.9, 8.5) 0.002
Both 17 (0.4) 8 (0.6) 9 (0.3) 0.3 (−0.2, 0.7) 0.22
Feeding route (%)
Normal diet 1738 (43.3) – 1738 (64.9) – –
Soft diet 942 (23.5) – 942 (35.1) – –
NGT-fed 225 (5.6) 225 (16.9) – – –
PEG-fed 7 (0.2) 7 (0.5) – – –
Intravenous/subcutaneous fluids 726 (18.1) 726 (54.5) – – –
No feeding fluids 373 (9.3) 373 (28.0) – – –
Neuroimaging (%)
Abnormal scan 3763 (97.6) 1274 (98.9) 2489 (96.9) 2.0 (1.1, 2.9) <0.001
Location
Lobar (ACA, MCA, or PCA) 1992 (51.6) 834 (64.8) 1158 (45.1) 19.7 (16.4, 22.9) <0.001
Lacunar 396 (10.3) 71 (5.5) 325 (12.7) −7.1 (−8.9, −5.3) <0.001
Brainstem or cerebellar 73 (1.9) 20 (1.6) 53 (2.1) −0.5 (−1.4, 0.4) 0.27
Mass effect, moderate to extreme 1178 (31.3) 542 (43.0) 636 (25.4) 17.6 (14.4, 20.8) <0.001
Previous stroke lesion(s) 2326 (60.5) 763 (59.3) 1563 (61.1) −1.8 (−5.1, 1.5) 0.28
Cerebral atrophy 3229 (84.0) 1086 (84.4) 2143 (83.8) 0.6 (−1.8, 3.1) 0.63
Leukoaraiosis 1644 (42.8) 566 (44.0) 1078 (42.1) 1.8 (−1.5, 5.2) 0.28
Data are number (%) or mean (standard deviation). Comparison by chi-square test or t test.
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Feeding Route and Outcome
Data on outcomes at days 7 and 90 were missing in 10
(0.25%) and 15 (0.37%) patients, respectively. Non-oral
feeding was associated with a worse outcome at day 7
with more deaths (+5.3%), death or neurological deteri-
oration (+11.7%) and worse impairment (SSS −1.3
points) (Table 2). During hospitalisation, patients who
were not on oral feeding had a longer hospital stay
(+6.8 days; Supplementary Fig. II), and were more
Fig. 1 Change in feeding route
from baseline to day 7 for all
patients. Comparison by adjusted
ordinal logistic regression. Note:
the first 40% of patients were all
on normal diet and are not shown
for clarity. Adjusted common
odds ratio 2.67, 95% CI 2.44–
2.93, 2p < 0.001
Table 2 Comparison of outcomes by feeding route at baseline
Number All No oral feeding Oral feeding OR/MD unadjusted 2p OR/MD adjusted 2p
Participants 1331 2680
Day 7
Death (%) 4001 119 (3.0) 86 (6.5) 33 (1.2) 5.54 (3.69, 8.32) <0.001 1.64 (1.02, 2.62) 0.040
Death or deterioration (%) 3991 378 (9.5) 229 (17.3) 149 (5.6) 3.52 (2.83, 4.38) <0.001 1.92 (1.48, 2.48) <0.001
SSS 3991 38.8 (16.1) 29.0 (17.4) 43.7 (12.9) −14.7 (−15.6, −13.7) <0.001 −1.3 (−2.0, −0.5) <0.001
Hospital
Length of stay (days) 3985 20.9 (23.6) 30.2 (28.9) 16.3 (18.8) 13.9 (12.4, 15.4) <0.001 6.8 (5.2, 8.5) <0.001
RTI, all (%)a 4011 257 (6.4) 183 (13.7) 74 (2.8) 5.61 (4.25, 7.42) <0.001 2.03 (1.46, 2.82) <0.001
RTI, fatal (%)a 4011 149 (3.7) 115 (8.6) 34 (1.3) 7.36 (4.99, 10.86) <0.001 2.32 (1.48, 3.64) <0.001
Admitted to SRU (%) 3984 2018 (50.7) 817 (61.8) 1201 (45.1) 1.97 (1.72, 2.26) <0.001 2.03 (1.73, 2.38) <0.001
SLT management (%) 3984 1979 (49.7) 951 (72.0) 1028 (38.6) 4.09 (3.54, 4.72) <0.001 3.51 (2.98, 4.15) <0.001
To institution (%) 3666 1157 (31.6) 577 (53.0) 580 (22.5) 3.89 (3.35, 4.52) <0.001 2.37 (1.99, 2.81) <0.001
Died (%) 4011 320 (8.0) 233 (17.5) 87 (3.2) 6.32 (4.90, 8.17) <0.001 1.98 (1.47, 2.67) <0.001
Day 90
Death (%) 3996 496 (12.4) 314 (23.6) 182 (6.8) 4.23 (3.47, 5.15) <0.001 1.35 (1.06, 1.71) 0.014
mRS (/6) 3995 3.1 (1.7) 4.0 (1.7) 2.7 (1.6) 1.3 (1.2, 1.4) <0.001 0.2 (0.1, 0.3) <0.001
Barthel Index (/100) 3970 64.4 (38.8) 43.1 (40.8) 75.0 (32.9) −32.0 (−34.3, −29.6) <0.001 −7.3 (−9.5, −5.0) <0.001
tMMSE (/19) 2032 11.0 (7.6) 6.8 (8.2) 13.0 (6.4) −6.2 (−6.8, −5.5) <0.001 −1.0 (−1.6, −0.3) 0.003
TICS (/37) 2013 14.7 (10.7) 9.1 (11.0) 17.4 (9.3) −8.4 (−9.3, −7.4) <0.001 −1.2 (−2.1, −0.3) 0.012
Animal naming 2366 9.3 (7.8) 5.9 (7.5) 10.9 (7.4) −5.0 (−5.7, −4.4) <0.001 −0.6 (−1.3, 0.0) 0.068
ZDS 3253 58.5 (24.1) 69.5 (26.5) 54.0 (21.5) 15.5 (13.8, 17.3) <0.001 4.1 (2.3, 5.9) <0.001
EQ-5D HUS (/1.0) 3952 0.5 (0.4) 0.3 (0.4) 0.5 (0.4) −0.3 (−0.3, −0.2) <0.001 −0.03 (−0.1, 0.0) 0.028
EQ-VAS 3440 56.1 (31.2) 42.5 (34.4) 62.0 (27.7) −19.5 (−21.6, −17.3) <0.001 −3.3 (−5.5, −1.1) 0.004
Not at homeb 3980 1326 (33.3) 751 (56.6) 575 (21.7) 4.72 (4.09, 5.45) <0.001 2.19 (1.85, 2.59) <0.001
Data are number (%) ormean (standard deviation) and odds ratio (OR)/mean difference (MD) (95% confidence intervals). Comparison by binary logistic
regression, or multiple linear regression, with adjustment
EQ-5D Euro-QoL-5 Dimension-3 level, EQ-VAS Euro-QoL-Visual Analogue Scale, HUS health utility status (derived from EQ-5D), RTI respiratory
tract infection, SLT speech and language therapy, SRU stroke rehabilitation unit, SSS Scandinavian Stroke Scale, TICS telephone interview of cognition
scale, tMMSE telephone mini-mental state examination, VAS visual analogue scale, ZDS Zung depression scale
a From serious adverse event reports
b Dead, still in hospital or in institution
124 Transl. Stroke Res. (2018) 9:120–129
likely to develop a respiratory tract infection or pneu-
monia (+10.9%), be admitted to a stroke rehabilitation
unit (+16.7%), be seen by a speech and language ther-
apist (+33.4%), be discharged to an institution (+30.5%)
or die in hospital (+14.3%). Similarly, outcomes at day
90 were significantly worse in the non-oral feeding
group, manifest as worse dependency (median mRS
+1.0 unit, Fig. 2), disability (Barthel Index −7.3 units),
cognitive impairment (telephone MMSE −1.0 unit),
mood disturbance (ZDS +4.1 unit) and quality of life
(health utility status −0.03, EQ-VAS −3.3) (Table 2),
as well as a higher rate of death (absolute increase
16.8%; Supplementary Fig. III).
Feeding Route and Respiratory Tract Infection
RTI was more likely to develop in patients with an
altered feeding route, adjusted common odds ratio
1.41, 95% CI 1.12–1.79, 2p = 0.004 (Supplementary
Fig. IV). In patients with non-oral feeding, RTI was
reported in 183 (pneumonia 173, chest infection 9,
COPD 1) of 1331 (13.7%) patients, with a median time
to presentation of 8.0 [2.0, 29.0] days from entry into
the trial (equivalent to ~9 days from stroke onset).
Development of pneumonia was not associated with
side of stroke: right lesion 127/2091 (6.1%) and left
lesion 111/1903 (5.8%) (2p = 0.75). Development of
RTI was associated with increased discharge to an insti-
tution (+29.1%) and death in hospital (+38.6%)
(Supplementary Table III). Similarly, outcomes were
worse at day 90 with increased death (+54.9%) and
worse dependency (mRS +1.0), disability, cognition,
mood and quality of life. The negative cognition scores reflect
that a majority of patients who were on non-oral feeding and
who developed RTI went on to die in hospital.
Glyceryl Trinitrate and Feeding Route
Overall, GTN had no effect on route of feeding at day
7 whether assessed in unadjusted or adjusted analyses
Fig. 2 Modified Rankin Scale at day 90. Distribution inmodified Rankin
Scale at day 90 between patients who were allowed to feed orally versus
those who were not allowed to feed orally at baseline. mRS 0:
independent and no symptoms; mRS 5: dependent with full care; mRS
6: dead. Comparison by adjusted ordinal logistic regression. Adjusted
common odds ratio 1.43 (95% confidence intervals 1.24–1.64,
2p < 0.001)
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(Supplementary Fig. V). When assessed in pre-
specified subgroups [17], an interaction (p = 0.011)
was present between GTN, feeding route and time to
treatment, with GTN appearing to improve feeding
route at day 7 in patients randomised within 6 h of
stroke onset (Fig. 3) . When focussing on this
subgroup, randomisation to GTN was associated
with a move to improved feeding route, common odds
ratio 0.61, 95% confidence intervals 0.38, 0.98;
p = 0.040 (Table 3; Supplementary Fig. VI) and a
tendency to less respiratory tract infection, including
pneumonia.
Fig. 3 Forest plot of effect of
GTN versus no GTN on feeding
route in pre-specified subgroups.
Comparison with ordinal logistic
regression with interaction term
added between subgroup and
GTN
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Discussion
These pre-specified [17] secondary exploratory analyses of the
ENOS trial confirm earlier data that swallowing problems,
assessed here using the surrogate of route of feeding, are common
immediately after stroke. Feeding route improved over the first
week, and was associated with a poor outcome apparent as in-
creased death, dependency, disability, impairment,
institutionalisation and pneumonia. Although GTN did not alter
feeding route overall, patients randomised to GTN within 6 h of
ictuswere less likely to require enteral feeding or parenteral fluids.
The observation that post-stroke swallowing problems are
common supports earlier studies [4]. Although many patients
improved their feeding route over the first week, some did not
and a minority worsened, as reported by others [1–3]. Factors
associated with increased death and dependency included pa-
tient characteristics (increased age, female sex), medical history
(more hypertension) and clinical presentation (more cortical
syndromes and higher stroke severity and blood pressure), as
published previously [4]. Further, dysphagia causes aspiration
of foods, liquids and oral secretions and therefore pneumonia
[5–7] and death [6], these observations also being seen here.
GTN, if given within 6 h of stroke, improved feeding route
at day 7. Although this finding could be due to chance, GTN
was associated with improved functional outcome when given
hyper-acutely in ENOS [19, 21] and ultra-acutely in the RIGHT
pre-hospital trial [22]. This raises the possibility that the im-
provement in dysphagia (and dependency) results from a reduc-
tion in stroke damage due, perhaps, to improved perfusion,
blood pressure lowering and/or neuroprotection. In this respect,
feeding route is likely to be a biomarker for stroke recovery
reflecting a change in phenotype from severe stroke (with
swallowing impairment) to a less severe level of stroke and
swallowing impairment. Nitric oxide donors also improve ex-
ercise tolerance [24] and so might reduce tiring during mastica-
tion and swallowing. GTN might also have improved
swallowing though relaxing oesophageal smooth muscle there-
by improving the oesophageal phase of swallowing, as seen
potentially in a small trial of nifedipine [13]. However, such a
mechanism would not be expected to be time-dependent and
GTN should therefore have improved feeding route irrespective
of recruitment time after stroke onset; further, direct effects on
smooth muscle would not explain apparent effects seen with
less dependency, disability, cognitive impairment and mood
disturbance, and improved quality of life [19, 21, 22].
Moreover, in the absence of direct measures of oesophageal
physiology such as a barium swallow or manometry, it is not
possible to say that oesophageal function was altered by GTN.
Indeed, oesophageal relaxation might promote gastro-
oesophageal reflux and the development of aspiration pneumo-
nia; in reality, there was no evidence for this across the main
trial [19] and a tendency to less pneumonia was seen in those
treated early with GTN. As a result, the effect of GTN on
feeding route is unlikely to be specific to swallowing.
The strengths of this study are its large size with data com-
ing from a high fidelity trial that recruited more than 4000
patients from 5 continents and 23 countries. Data on feeding
route at baseline were complete, and the findings consistent
across outcomes. Hence, the results are likely to exhibit both
internal and external validity. Nevertheless, several caveats
need to be made. First, dysphagia was not routinely diagnosed
using techniques such as videofluoroscopy or fibreoptic
Table 3 Comparison of
outcomes by randomised
treatment, GTN versus no GTN,
in patients randomised within 6 h
of stroke onset
Number All GTN No GTN OR 2p
Participants 273 144 129
Day 7
Feeding route [/7]a 270 1 [1, 2] 1 [1, 2] 1 [1, 2] 0.61 (0.38, 0.98) 0.040
Feeding, non-oral 264 42 (15.9) 18 (12.6) 24 (19.8) 0.58 (0.30, 1.13) 0.11
Hospital
RTI, allb 273 12 (4.4) 3 (2.1) 9 (7.0) 0.28 (0.08, 1.07) 0.063
RTI, fatal 273 8 (2.9) 1 (0.7) 7 (5.4) 0.12 (0.01, 1.00) 0.05
Admitted to SRU 268 101 (37.7) 52 (36.4) 49 (39.2) 0.89 (0.54, 1.45) 0.63
Discharge to institution 243 73 (30.0) 40 (29.6) 33 (30.6) 0.96 (0.55, 1.66) 0.88
Died 273 25 (9.2) 8 (5.6) 17 (13.2) 0.39 (0.16, 0.93) 0.034
Day 90
Feeding: unable/need helpc 236 74 (31.4) 36 (27.1) 38 (36.9) 0.63 (0.36, 1.10) 0.11
Data are number (%), median [interquartile range] and odds ratio (OR)/(95% confidence intervals). Comparison
by binary logistic regression or ordinal logistic regression
RTI respiratory tract infection, SRU stroke rehabilitation unit,
a Feeding status:1 normal diet, 2 soft diet, 3 NGT-fed, 4 PEG-fed, 5 IV/SC fluids, 6 no feeding/fluids, 7 death
b From serious adverse event reports
c From Barthel Index
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endoscopy, and clinical decisions on how to feed were based
on local guideline-based practice that will have varied consid-
erably across the 173 recruiting sites. As a result, we used
route of feeding as a proxy for presumed or diagnosed dys-
phagia. One common model of care will have consisted of
nurses performing a water-based screening test [25]; if
swallowing was unsafe, they will have put the patient ‘nil by
mouth’, and referred patients on to speech and language ther-
apists for formal swallowing assessment and dieticians for
provision of nutrition. Equally, some patients (almost 10%
here) received no fluids or feeding over the first week.
Although reasons were not collected, some physicians believe
that the resulting dehydrating will reduce the development of
cerebral oedema in patients with severe stroke; additionally,
this may have reflected placing the patient on a care of the
dying pathway. Although conceivable in a single-blind trial, it
seems unlikely that any of these decisions will have been
determined on the basis on randomised ENOS treatments.
Second, the feeding route scale used here is novel and not
validated although it was defined prospectively and collected
from the start of the trial in 2001 [17]; further, it is easy to
assess clinically and its components exhibit face, content and
construct validity. A criticism of the use of this scale at base-
line is inclusion of PEG-feeding since this is most likely to
represent a PEG from before the index stroke as acute PEG
insertion within 48 h of stroke onset is not common practice.
Third, ENOS mostly included patients with anterior circula-
tion strokes (as is typical for most acute stroke trials) and so
those with posterior strokes were underrepresented. Since
there are differences in the role of brain regions in controlling
swallowing, especially between hemispheres and brain stem,
the results seen here may not be representative for posterior
circulation strokes. Fourth, although information on the treat-
ment of dysphagia during admission was not collected, more
patients with non-oral feeding were seen by a speech and
language therapist; this is most likely to have been for
swallowing rather than speech problems. Fifth, some patients
may have had pre-existing dysphagia, either due to a previous
stroke or for another reason, and this information was not
collected; 14.8% of patients reported a history of previous
stroke and about half of these may have had this complicated
by dysphagia, at least during the early phase of recovery.
Previous dysphagia would then have made it less likely that
patients would recover from the index swallowing problems.
Sixth, data on pneumonia and chest infection came from seri-
ous adverse event reports and definitions were not
operationalised; hence, the number of events will probably
have been underestimated. Although investigator reporting
of RTI may have been biased by knowledge of treatment
assignment, it is unlikely that this would explain the magni-
tude of effects seen here. Last, information on other
dysphagia-related outcomes such as malnutrition, body
weight or albumin levels were not collected in the trial.
In summary, the route of feeding was abnormal in a signif-
icant minority of patients with acute stroke, with many of
these recovering over the first week; non-oral feeding was
associated with poor outcome. Trials of potential treatments
for post-stroke dysphagia are urgently needed. The potential
benefit of GTN on feeding route is being tested as a secondary
outcome in the ongoing phase III RIGHT-2 trial of GTN given
in the ultra-acute phase after stroke (http://right-2.ac.uk). The
route of feeding scale used here is novel and needs further
assessment but is pragmatic and uses readily available
information so may prove useful in the future.
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